Repeat treatment of rheumatoid arthritis patients with a murine anti- intercellular adhesion molecule 1 monoclonal antibody

Arthur F. Kavanaugh, Hendrik Schulze-Koops, Laurie S. Davis, Peter E. Lipsky

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Objective. To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in active rheumatoid arthritis (RA). Methods. In an open-label study, 8 patients who had previously received a course of anti- ICAM-1 MAb received a second course. Results. The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course. Conclusion. Repeated courses of therapy with a murine MAb to ICAM-1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.

Original languageEnglish (US)
Pages (from-to)849-853
Number of pages5
JournalArthritis and Rheumatism
Volume40
Issue number5
StatePublished - 1997

Fingerprint

Intercellular Adhesion Molecule-1
Rheumatoid Arthritis
Monoclonal Antibodies
Therapeutics
Antigen-Antibody Complex
Safety

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Repeat treatment of rheumatoid arthritis patients with a murine anti- intercellular adhesion molecule 1 monoclonal antibody. / Kavanaugh, Arthur F.; Schulze-Koops, Hendrik; Davis, Laurie S.; Lipsky, Peter E.

In: Arthritis and Rheumatism, Vol. 40, No. 5, 1997, p. 849-853.

Research output: Contribution to journalArticle

@article{03a5e66e4bb74a419dd0256c60bb0197,
title = "Repeat treatment of rheumatoid arthritis patients with a murine anti- intercellular adhesion molecule 1 monoclonal antibody",
abstract = "Objective. To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in active rheumatoid arthritis (RA). Methods. In an open-label study, 8 patients who had previously received a course of anti- ICAM-1 MAb received a second course. Results. The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course. Conclusion. Repeated courses of therapy with a murine MAb to ICAM-1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.",
author = "Kavanaugh, {Arthur F.} and Hendrik Schulze-Koops and Davis, {Laurie S.} and Lipsky, {Peter E.}",
year = "1997",
language = "English (US)",
volume = "40",
pages = "849--853",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Repeat treatment of rheumatoid arthritis patients with a murine anti- intercellular adhesion molecule 1 monoclonal antibody

AU - Kavanaugh, Arthur F.

AU - Schulze-Koops, Hendrik

AU - Davis, Laurie S.

AU - Lipsky, Peter E.

PY - 1997

Y1 - 1997

N2 - Objective. To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in active rheumatoid arthritis (RA). Methods. In an open-label study, 8 patients who had previously received a course of anti- ICAM-1 MAb received a second course. Results. The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course. Conclusion. Repeated courses of therapy with a murine MAb to ICAM-1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.

AB - Objective. To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in active rheumatoid arthritis (RA). Methods. In an open-label study, 8 patients who had previously received a course of anti- ICAM-1 MAb received a second course. Results. The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course. Conclusion. Repeated courses of therapy with a murine MAb to ICAM-1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.

UR - http://www.scopus.com/inward/record.url?scp=0030911156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030911156&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 849

EP - 853

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -